


# Green Project Report

Board Meeting

June 4, 2015

# Summary of activities in 2014-2015

- Completing GP membership directory (>110)
- Monthly GP meeting,
- Phone conferences
- Facebook SNUCM
- Annual Convention



# GP Scientific Presenters in Annual Convention

Name	Specialty	Institute
Ahn Kyungheup 96	Psychiatry	Yale, CT
Choi Taewoong 02	Hem-Onc	U Pittsburg, PA
Huh Wonjae 02	Pathology	Vanderbilt, TN
Jang Sekwon 01	Onc	Fairfax, VA
Jeong Yountae 01	Hem Onc	Stanford, CA
Joung Kyounggeun 02	Ped, Neonatology	Morristown, NJ
Kim Junghoon 98		
Kim Taekon 01	Hem Onc	Yale
Kim Yuhree	Epidemiology	Johns Hopkins
Lee Taehoon 02	G-I, Hepatology	OH
Nam Youngjae 94	Cardiology	Vanderbilt
Park Eunkyung 00	PET, Nuclear Medicine	Yale
Park Youngsu 08	Family Planning Project in Ethiopia	Stanford, CA
Song Kyungmin 09	Healthcare, MPH Consulting firm	DC

- **Biosketch**  
**Example of**  
**Presenting**  
**GP**  
**members**

## **MEK Inhibitors Selectively Suppress Alloreactivity and Graft-versus-Host Disease in a Memory Stage-dependent Manner**

**Tae Kon Kim, M.D. (2001)**

Clinical fellow, medical oncology/hematology

Department of Internal Medicine, Yale University School of Medicine,  
Smilow Cancer Hospital at Yale-New Haven Hospital, New Haven, CT

Immunosuppressive strategies currently used in hematopoietic stem cell transplantation reliably decrease graft-versus-host disease (GVHD) rates, but also impair pathogen-specific immunity. Experimental transplant studies indicate that GVHD-initiating alloreactive T cells reside primarily in naive and central memory T-cell compartments. In contrast, virus-specific T-cells comprise a more differentiated memory population. Previously, it was shown that the rat sarcoma/mitogen-activated protein kinase kinase/extracellular receptor kinase (RAS/MEK/ERK) pathway is preferentially activated in naive and central memory human T-cells.

We hypothesized that MEK inhibitors would preferentially inhibit alloreactive T-cells, while sparing more differentiated virus-specific T-cells. To test this, we examined MEK inhibitors including selumetinib for human T cells. We found that these agents preferentially inhibited cytokine production and alloreactivity mediated by naive and central memory human CD4(+) and CD8(+) T-cells while sparing more differentiated T-cells specific for the human herpesviruses, cytomegalovirus and Epstein-Barr virus.

Next, we examined possible therapeutic potential in vivo conditions. We found that short-term posttransplant administration of selumetinib in a major histocompatibility complex major- and minor-mismatched murine model significantly delayed the onset of GVHD-associated mortality without compromising myeloid engraftment, demonstrating the in vivo potential of MEK inhibitors in the setting of hematopoietic stem cell transplantation. These findings strongly suggest that targeting memory-dependent differences in T-cell signaling is a potent and selective approach to inhibition of alloreactivity.

### **Tae Kon Kim (01) Hematology/Oncology**

Clinical fellow in medical oncology/hematology

Yale University, New Haven, CT



Dr. Tae Kon Kim graduated from SNUCM in 2001 and completed his internship (PGY-1) at SNUH, with the 'Intern of the Year' award. To pursue a physician scientist career, he joined the laboratory of Dr. Alan Gewirtz's at the University of Pennsylvania and studied leukemia biology. Subsequently, he moved to MD Anderson Cancer Center, completed graduated studies and obtained Ph.D. in immunology in 2010. Based on his Ph.D. work, he published three first author papers including a Plenary paper in the Blood, and 5 co-authored papers and presented data at many national and international meetings (ASH, ASBMT, AAI etc.). He then completed residency in medicine at University of Miami in 2013 and currently is a clinical fellow in medical oncology/hematology at Yale Cancer Center. Dr. Kim lives in New Haven, CT with his wife and two daughters.

# Green Project Forum I

## June 5th, 2015, Saturday

- 12:15-1:15 Lunch  
12:45-1:45 Private Practice Building (overlap with lunch)  
**Moderator: Wonsock Shin, MD (1988)**  
Panel: Sung Eun Yu, MD (1994), In Bo Sim, MD (1983)  
Wonsock Shin, MD (1988)
- 1:45-2:00 Break  
2:00-3:45 Research Career Development  
**Moderator: Chang-Gyu Hahn, MD, PhD (1981), Young-Jae Nam, MD, PhD (1994)**  
3:45-4:00 Introduction of Gastric Cancer Project: Chan Hyung Park, MD (1962)

## June 6th, 2015, Sunday

- 8:00-10:00 GP Forum Open Discussion with Breakfast  
**Moderator: Mooyeon Oh-Park, MD (1989), Sunhee Lee, MD (1981)**  
Reflection on Convention  
Past, Present, and Future of GP  
Women in Medicine & Science  
Collaboration with SNUCM  
**Moderator: Eun Yong, MD (2014)**  
Communications, Social Networking Services

### Sung-Eun Yoo (94) Endocrinology

\*Green Project "Medical Practice Building" Panel Discussant



Sung-Eun Yoo, MD, FACE, is a graduate of Seoul National University Medical School in 1994. After graduation and internship at the Seoul National University hospital, she moved to Boston, MA. She trained as a postdoctoral fellow in the division of Endocrinology, Beth-Israel Hospital from 1995 to 1997. Subsequently she completed an internship and residency program in internal medicine at the University of Cincinnati Medical Center, followed by fellowship training in endocrinology, diabetes and metabolism at the University of Cincinnati medical center and University of North Carolina- Chapel Hill.

Dr. Yoo has held a position of clinical assistant professor of medicine in the division of Endocrinology at University of North Carolina- Chapel Hill from 2006 to 2011 until she opened

# Green Project Forum II & III

- Research Career Development (Saturday)
  - Dr. 한창규 & Dr. 남영재
- Status of women in medicine in SNU
  - Dr. 이선희
- Collaboration with SNUCM
  - Dr. 오무연
- Communication via IT
  - Dr. 은용